AstraZeneca Beats Expectations, Raises Guidance After Strong Q1 Results
Pharmaceutical giant AstraZeneca reported stronger‑than‑expected first‑quarter earnings and lifted its full‑year outlook, driven by robust sales of its oncology and respiratory drugs. Analysts praised the improved guidance, noting it supports the company's growth narrative.
Advertisement: Article Inline